Natarajan Muthusamy, DVM, PhD
College of Medicine
>Leukemia, Lymphocytic, Chronic, B-Cell ● Cancer ● Leukemia ● Lymphoma, Mantle-Cell ● Leukemia, Myeloid, Acute ● Precursor Cell Lymphoblastic Leukemia-Lymphoma ● Hematologic Cancer
Natarajan Muthusamy, DVM, PhD, is a member of the Leukemia Research Program at the OSUCCC – James. His research focuses on several areas, including biological therapies for hematologic malignancies, the development and characterization of clinically relevant animal models of lymphoid malignancies, and targeted delivery of RNA-based therapeutics in lymphoid and myeloid malignancies.One of his recently published research projects resulted in findings that suggest an alternative mechanism for induction of IL-21 receptor in chronic lymphocytic leukemia (CLL) B cells and provide a basis for creation of future combination therapies. He is also the co-inventor of a dozen industry-related innovations and co-holds two U.S. patents, including one for therapeutic agents for lymphoid malignancies. Dr. Muthusamy has co-authored over 100 articles appearing in well-respected journals, such as Biology of Blood and Marrow Transplantation, American Journal of Hematology, Leukemia and Molecular Pharmaceutics. He has made numerous presentations to scientific gatherings, including the Translational Research Cancer Centers Consortium, International Congress on Hematologic Malignancies and European Conference on Tetraspanins.